The study will test a medication called glepaglutide, which is given as an injection under the skin twice each week. Some participants will receive glepaglutide while others will receive placebo. The purpose of this study is to confirm whether glepaglutide can help reduce the amount of parenteral support that people with short bowel syndrome need each week. The study will look at whether the medication can decrease the volume of nutrition and fluids that must be given through the veins, and possibly help some people reduce the number of days per week they need this support or even stop needing it completely.

The study is divided into two parts. In the first part, which lasts 24 weeks, participants will be randomly assigned to receive either glepaglutide or placebo, and neither the participants nor the doctors will know which treatment is being given. This part will continue for up to 52 weeks for some measurements. After this, there will be a longer period where all participants will receive glepaglutide and everyone will know they are receiving the actual medication. During the study, doctors will measure changes in the weekly volume of parenteral support needed and track how participants feel about their condition overall.

The purpose of this study is to evaluate the safety and how well glepaglutide works over a longer period of time in adults with short bowel syndrome who have already been taking this medicine in previous studies. The study will last for 104 weeks, which is about two years, and patients will receive glepaglutide injections twice a week at a dose of 10 milligrams. This is an extension study, meaning it is designed for patients who are already being treated with glepaglutide in earlier trials and want to continue receiving the medicine.

During the study, doctors will monitor patients regularly to check for any unwanted effects and to see if the medicine continues to help reduce the amount of nutritional support that patients need through their veins, which is called parenteral support. The study will track changes in the weekly amount of parenteral support that patients require from the beginning of the study until the end of treatment at 24 months. All patients in this study will receive glepaglutide, and there is no placebo group in this trial.

Participants in the study will be divided into different groups. Some groups will include patients with Short Bowel Syndrome who have not previously taken Apixaban or Teduglutide, while others will include patients who are already on these medications. There will also be a group of healthy volunteers without any history of gastrointestinal issues. The study will compare the levels of Apixaban in the blood after taking different doses of the medication, to see if there are differences between those with and without Short Bowel Syndrome.

The study will take place over a period of time, with participants receiving either Apixaban or a placebo. The goal is to better understand how Apixaban is absorbed and processed in the body, which could help improve treatment options for patients with Short Bowel Syndrome who need long-term nutritional support.

Participants in the study will take rivaroxaban, which is a medication used to prevent blood clots, in the form of film-coated tablets. The study will observe the effects of this medication over a period of at least one year. During this time, researchers will monitor the participants’ health outcomes, such as the occurrence of blood clots or bleeding events, and compare these with laboratory tests that measure the levels of rivaroxaban in the blood. The study will also assess the quality of life of the participants using a standard questionnaire.

The study aims to provide valuable insights into how rivaroxaban affects patients with short bowel syndrome who are dependent on long-term parenteral nutrition. By understanding the relationship between the medication’s blood levels and clinical outcomes, the study hopes to improve treatment strategies for these patients. The research will also explore how different individuals absorb the medication, which can vary from person to person.

The purpose of the study is to assess the safety and tolerability of HM15912 when given through multiple subcutaneous injections over a period of 24 weeks. Participants will receive these injections under the skin, and the study will monitor how the body processes the medication, which is known as its pharmacokinetic profile. The trial will also look at how the treatment affects the need for parenteral nutrition or intravenous fluids, which are methods of providing nutrition directly into the bloodstream.

Throughout the study, participants will be closely monitored for any side effects or reactions at the injection site. The trial will also include regular checks of vital signs, such as heart rate and blood pressure, and may involve tests like a 12-lead electrocardiogram (ECG) to ensure the treatment is safe. The study aims to provide valuable information on how HM15912 can help manage Short Bowel Syndrome-associated Intestinal Failure and improve the quality of life for those affected by this condition.

The purpose of the study is to assess the safety and initial effectiveness of Crofelemer in adults with SBS-IF. Participants will be randomly assigned to receive either Crofelemer or a placebo, which is a substance with no active medication. The study will be conducted in a double-blind manner, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo. This approach helps ensure that the results are unbiased. The study will last for 24 weeks, during which participants will take the medication and attend regular check-ups to monitor their health and any changes in their condition.

Throughout the study, researchers will closely observe the frequency of any side effects and how the treatment affects the participants’ need for parenteral support, which is the intravenous delivery of nutrients and fluids. The study aims to determine if Crofelemer can reduce the volume of parenteral support needed and improve stool consistency. Participants will also be monitored for any changes in their overall health, including liver and kidney function, as well as glucose and lipid levels. This trial is an important step in exploring new treatment options for those living with SBS-IF.

The purpose of this study is to evaluate the long-term safety of Glepaglutide treatment in adults who have completed a previous trial. Participants will receive Glepaglutide injections and will be monitored over a period of 104 weeks, which is approximately two years. During this time, researchers will collect information on any side effects or changes in health that occur. The study aims to ensure that Glepaglutide is safe for long-term use and to observe its effects on the participants’ health and well-being.

Throughout the study, participants will have regular check-ups to monitor their vital signs, such as heart rate and blood pressure, and to perform tests like blood work and urinalysis. These assessments will help researchers understand how the body responds to Glepaglutide over time. The study will also look at how the medication affects the need for parenteral support, which is a method of feeding that bypasses the usual process of eating and digestion. The goal is to see if Glepaglutide can reduce the amount of parenteral support needed by patients with SBS.

The purpose of this study is to evaluate how safe Glepaglutide is for long-term use in people with Short Bowel Syndrome. Participants in the study will receive either Glepaglutide or a placebo, which is a substance with no active medication. The study will monitor participants over a period to observe any changes in their condition and to ensure the treatment is safe. The study will also look at how well the treatment works in reducing the need for parenteral support, which is a method of feeding that bypasses the usual process of eating and digestion.

Throughout the study, participants will receive regular check-ups to monitor their health, including assessments of vital signs, heart function through an electrocardiogram (ECG), and various blood and urine tests. The study aims to see if Glepaglutide can help reduce the volume of parenteral support needed and improve the overall quality of life for those with Short Bowel Syndrome. The trial is expected to continue until 2026, providing valuable information on the long-term use of Glepaglutide in managing this condition.

The purpose of this research is to assess the long-term safety and how well patients tolerate apraglutide when used over an extended period. The medication will be given as an injection under the skin (subcutaneous injection) using a pre-filled syringe that contains both powder and liquid that need to be mixed before use.

During this long-term study, participants will receive treatment for up to 312 weeks (approximately 6 years). Throughout the study, doctors will monitor various aspects of participants’ health, including their need for nutritional support through veins (parenteral support), body weight, sleep quality, and overall quality of life. Regular check-ups will be conducted to ensure participant safety and evaluate how well the treatment is working.